EGATEN for Treatment of Fascioliasis

February 18, 2019

By Drew Boxler

News

Article

Anthelmintic tablet for patients 6 years of age and older.

EGATEN^™ (triclabendazole, Novartis)

Indications: treatment of fascioliasis in patients six years of age or older

Dosage:

2 doses of 10 mg/kg given 12 hours apart in patients age 6 years of age or older
Take orally with food

Can be swallowed whole, divided in half and taken with water, or crushed and administered with applesauce
âRound dose upwards if unable to adjust exactly

Contraindications: known hypersensitivity to triclabendazole, other benzimidazole derivatives or any of the excipients in EGATEN

Click here for more prescribing information

Related Content

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara

November 12th 2024

Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff

August 6th 2020

Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia

Lauren Biscaldi, MS, Managing Editor

November 5th 2024

Article

The drug is also approved to treat schizophrenia and bipolar depression.

FDA Approves Journey Medical’s Emrosi for Rosacea

Lauren Massaro

November 5th 2024

Article

“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.

FDA Expands OA REMS, Mandates Mail-Back Envelopes for Opioid Analgesics

Lauren Massaro

November 4th 2024

Article

The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.